Articles from Kronos Bio, Inc.

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. ("Kronos Bio") (Nasdaq: KRON), a biotechnology company that has been developing small molecule therapeutics to address cancers and other diseases driven by deregulated transcription, today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with Concentra Biosciences, LLC ( “Concentra”), whereby Concentra will acquire Kronos Bio for $0.57 in cash per share of Kronos Bio common stock (“Kronos Bio Common Stock”), plus one non-tradeable contingent value right ("CVR"), which represents the right to receive: (i) 50% of the net proceeds in the case of a disposition of the Company’s product candidates known as KB-9558 and KB-7898 that occurs within 2 years following closing; (ii) 100% of the net proceeds in the case of a disposition of the Company’s product candidates known as KB-0742, lanraplenib and entospletinib that occurs prior to closing; (iii) 100% of cost savings realized prior to closing; (iv) 80% of cost savings realized between the merger closing date and the second (2nd) anniversary of the merger closing date; and (v) 50% of cost savings realized between the second (2nd) anniversary of the merger closing date and the third (3rd) anniversary of the merger closing date, each pursuant to the contingent value rights agreement (the “CVR Agreement”).

SAN MATEO, Calif., and CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a biopharmaceutical company, today reported fourth quarter and full year 2024 financial results.

– Norbert Bischofberger, Ph.D., is stepping down from his role as President & CEO –

– Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammatory signaling pathways, including antibodies and cytokine production, in ex vivo and in vivo models at well tolerated exposures –

– Discontinuing development of istisociclib, a CDK9 inhibitor; benefit-risk profile in platinum-resistant high-grade serous ovarian cancer does not support further development –

– Data demonstrates Kronos Bio's approach to targeting oncogenic transcription factors and the strong relationship between IRF4 and p300 in Multiple Myeloma –

– Preclinical data demonstrate that inhibiting the p300 KAT domain reactivates p53 in HPV-driven tumors resulting in anti-tumor activity –

– Data show that p300 KAT inhibitor KB-9558 was highly selective against human papillomavirus (HPV) oncoproteins E6 and E7, and therefore drove anti-tumor effects –

– KB-7898, a p300 KAT inhibitor, is the Company's first development candidate for autoimmune diseases and originates from its proprietary discovery engine that decodes complex transcription factor regulatory networks –

– Through selective inhibition of proinflammatory transcription, p300 KAT inhibition modulates the activity and function of multiple pro-inflammatory signaling pathways that drive chronic inflammatory diseases –

– New data show istisociclib (KB-0742) triggered cell death in preclinical ovarian cancer models of platinum and PARP-inhibitor (PARPi) resistance –

SAN MATEO, Calif., and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced the following upcoming conferences:

— First patient in platinum-resistant high-grade serous ovarian cancer cohort was dosed on optimized dose and schedule with istisociclib (KB-0742); expect data update in 1H 2025 —

— KB-0742 cleared 80mg four-days-on, three-days-off dosing schedule in dose escalation —

— KB-0742 continues to demonstrate a manageable safety and tolerability profile with no grade 3/4 neutropenia observed —

SAN MATEO, Calif. and CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that the company would participate in three upcoming healthcare conferences and events. Norbert Bischofberger, Ph.D., president and chief executive officer, will represent the company at these events.

SAN MATEO, Calif. and CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that it has appointed Deborah Knobelman, Ph.D., as Chief Operating Officer and Chief Financial Officer effective June 3, 2024. Dr. Knobelman will oversee the finance, accounting, business development, investor relations and corporate strategy functions.

— $152.0 million cash runway into the second half of 2026 —

SAN MATEO, Calif. and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present a study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors from the ongoing Phase 1/2 trial, KB-0742-1001 (NCT04718675), at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held from May 31 – June 4, 2024 in Chicago, Illinois and online.

Phase 1/2 study of KB-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; topline data from expansion cohort at this schedule expected in the first half of 2025

Company to assess KB-0742 at planned new dose schedule in ongoing phase 1/2 study; topline data from expansion cohort at new dose schedule expected in the first half of 2025

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that three abstracts have been selected for presentation at the American Association for Cancer Research (AACR) annual meeting, being held from April 5-10, 2024 in San Diego, California.

SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced participation in the 44th Annual Cowen Health Care Conference, taking place March 4-6, 2024, in Boston, Massachusetts.

Company eliminates three executive officer roles and appoints new Executive Leadership team

Phase 1b portion of phase 1b/2 lanraplenib study in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia completed; review of data does not support continuing to phase 2

SAN MATEO, Calif. and CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that Jorge DiMartino M.D., Ph.D., chief medical officer and executive vice president of clinical development, and Charles Lin, Ph.D., senior vice president of TRN mapping will participate in a fireside chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference on Wednesday, December 6, 2023 at 11:00 a.m. ET.

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that Norbert Bischofberger, Ph.D., president and chief executive officer, Jorge DiMartino M.D., Ph.D., chief medical officer and executive vice president of clinical development, and Charles Lin, Ph.D., senior vice president of TRN Mapping will participate in a fireside chat at the 35th Annual Piper Sandler Healthcare Conference on Tuesday, November 28, 2023 at 4:00 p.m. ET.

Company presented positive preliminary data from Phase 1 dose escalation portion of Phase 1/2 KB-0742 study at the AACR-NCI-EORTC and CTOS conferences

Strategic resource allocation to fully explore KB-0742’s potential in both dose escalation and expansion cohorts across multiple tumor types in its ongoing Phase 1/2 study

Brian Van Tine, M.D., of Washington University School of Medicine, shares data from the ongoing phase 1/2 KB-0742 clinical study that clearly corresponds with the findings from the pre-clinical studies at leading international sarcoma meeting

Brian Van Tine, M.D., of Washington University School of Medicine to share data from the ongoing Phase 1/2 study at leading international sarcoma meeting

Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors

Management to host conference call and webcast on October 13 at 4:30 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D., of City of Hope

SAN MATEO, Calif. and CAMBRIDGE, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, announced that its Chief Financial Officer and Head of Corporate Development, Yasir Al-Wakeel, BM BCh, will resign from his position to pursue a new professional opportunity as the chief executive officer of a private biotechnology company. The Company has initiated a search to identify a suitable replacement for Dr. Al-Wakeel, who will remain with Kronos Bio until September 15, 2023 to ensure business continuity.

Data from the Phase 1 dose escalation portion of the Phase 1/2 KB-0742 study will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2023

Dr. Besman brings more than 25 years of regulatory affairs and drug development experience and a track record of successfully advancing clinical programs

SAN MATEO, Calif. and CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences:

Enrollment ongoing in expansion portion of Phase 1/2 KB-0742 study, with initial efficacy data expected in 2H 2023

SAN MATEO, Calif. and CAMBRIDGE, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Roger Dansey, M.D., to the company’s Board of Directors. Dr. Dansey brings extensive experience in oncology drug development and a proven track record in the biotechnology industry. He currently serves as president, research and development of Seagen Inc.

Katherine Vega Stultz appointed to Board

First patient dosed in expansion portion of KB-0742 Phase 1/2 study, with initial efficacy results expected in 2H 2023

SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced participation in the 43rd Annual Cowen Health Care Conference, taking place March 6-8, 2023, in Boston, Massachusetts.

Kronos Bio will receive a $20 million upfront payment and could receive up to an additional $554 million in milestone payments

Lanraplenib is being evaluated in ongoing Phase 1b/2 trial in combination with gilteritinib in patients with relapsed/refractory FLT3-mutated AML

Kronos Bio to move into Phase 2 stage of study, evaluating compound in patients with MYC-amplified and other transcriptionally addicted tumors

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences:

Earlier today, the company announced prioritization of clinical portfolio to focus on next-generation SYK inhibitor, lanraplenib and CDK9 inhibitor, KB-0742

Company to discontinue Phase 3 entospletinib trial for strategic reasons

Company Plans to Provide Update and Recommended Phase 2 Dose from Ongoing KB-0742 Phase 1/2 Clinical Trial in Q4 2022